![]() |
|
|
Vol. 298, Issue 2, 469-476, August 2001
Departments of Pharmacology and Toxicology (L.C., X.T.G., J.V.H.,
M.K.), Medicine (Q.F., X.L.), and Pathology (S.C.), University of
Western Ontario, London, Ontario, Canada
Pulmonary hypertension results in compensatory right ventricular
(RV) hypertrophy. We studied the role of the
Na+-H+ exchange (NHE) in the latter process by
determining the effect of the NHE-1 inhibitor cariporide after
monocrotaline-induced pulmonary artery injury. Sprague-Dawley rats
received a control or cariporide diet for 7 days, at which time they
were administered either monocrotaline (60 mg/kg) or its vehicle.
Twenty-one days later, monocrotaline control, but not cariporide-fed
animals, demonstrated increased RV weights and cell size of 65 and
52%, respectively. Monocrotaline alone significantly increased RV
systolic pressure and end diastolic pressure by 70 and 94%,
respectively, whereas corresponding values with cariporide were
significantly reduced to 33 and 42%. Central venous pressure
increased by 414% in control animals, which was significantly reduced
by cariporide. Monocrotaline treatment produced a decrease in cardiac
output of 28 and 8% in the absence or presence of cariporide
(P < 0.05 between groups), respectively. Although
body weights were significantly lower in both
monocrotaline-treated groups compared with vehicle treatment,
with cariporide the net gain in body weight was twice that seen
in the monocrotaline-treated animals without cariporide. Monocrotaline
also increased RV NHE-1 and atrial natriuretic peptide mRNA expression,
which was abrogated by cariporide. Monocrotaline-induced myocardial
necrosis, fibrosis, and mononuclear infiltration was completely
prevented by cariporide. Cariporide had no effect on monocrotaline-induced pulmonary intimal wall thickening. Our results demonstrate that cariporide directly attenuates myocardial dysfunction after monocrotaline administration independent of pulmonary vascular effects. NHE-1 inhibition may represent an effective adjunctive therapy that selectively targets myocardial hypertrophic responses in
pulmonary vascular injury.
This article has been cited by other articles:
![]() |
X. Li, P. Karki, L. Lei, H. Wang, and L. Fliegel Na+/H+ exchanger isoform 1 facilitates cardiomyocyte embryonic stem cell differentiation Am J Physiol Heart Circ Physiol, January 1, 2009; 296(1): H159 - H170. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. T. Steffen, S. J. Lees, and F. W. Booth Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia J Appl Physiol, December 1, 2008; 105(6): 1950 - 1958. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. McMurtry, S. Bonnet, E. D. Michelakis, S. Bonnet, A. Haromy, and S. L. Archer Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin-simvastatin study Am J Physiol Lung Cell Mol Physiol, October 1, 2007; 293(4): L933 - L940. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Akhavein, E. J. St.-Michel, E. Seifert, and C. V. Rohlicek Decreased left ventricular function, myocarditis, and coronary arteriolar medial thickening following monocrotaline administration in adult rats J Appl Physiol, July 1, 2007; 103(1): 287 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. E. Cingolani and I. L. Ennis Sodium-Hydrogen Exchanger, Cardiac Overload, and Myocardial Hypertrophy Circulation, March 6, 2007; 115(9): 1090 - 1100. [Full Text] [PDF] |
||||
![]() |
F. Cuello, A. K. Snabaitis, M. S. Cohen, J. Taunton, and M. Avkiran Evidence for Direct Regulation of Myocardial Na+/H+ Exchanger Isoform 1 Phosphorylation and Activity by 90-kDa Ribosomal S6 Kinase (RSK): Effects of the Novel and Specific RSK Inhibitor fmk on Responses to {alpha}1-Adrenergic Stimulation Mol. Pharmacol., March 1, 2007; 71(3): 799 - 806. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 31 - 45. [Abstract] [PDF] |
||||
![]() |
A. Baartscheer, C. A. Schumacher, M. M.G.J. van Borren, C. N.W. Belterman, R. Coronel, T. Opthof, and J. W.T. Fiolet Chronic inhibition of Na+/H+-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure Cardiovasc Res, January 1, 2005; 65(1): 83 - 92. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. V. Mukhin, M. N. Garnovskaya, M. E. Ullian, and J. R. Raymond ERK Is Regulated by Sodium-Proton Exchanger in Rat Aortic Vascular Smooth Muscle Cells J. Biol. Chem., January 16, 2004; 279(3): 1845 - 1852. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chen, C. X. Chen, X. T. Gan, N. Beier, W. Scholz, and M. Karmazyn Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H381 - H387. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Karmazyn, Q. Liu, X. T. Gan, B. J. Brix, and L. Fliegel Aldosterone Increases NHE-1 Expression and Induces NHE-1-Dependent Hypertrophy in Neonatal Rat Ventricular Myocytes Hypertension, December 1, 2003; 42(6): 1171 - 1176. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Avkiran and R. S Haworth Regulatory effects of G protein-coupled receptors on cardiac sarcolemmal Na+/H+ exchanger activity: signalling and significance Cardiovasc Res, March 15, 2003; 57(4): 942 - 952. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, A. J. Misik, C. V. Rieder, R. J. Solaro, A. Lowen, and L. Fliegel Thyroid Hormone Receptor alpha 1 Regulates Expression of the Na+/H+ Exchanger (NHE1) J. Biol. Chem., August 2, 2002; 277(32): 28656 - 28662. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. V. Rieder and L. Fliegel Developmental regulation of Na+/H+ exchanger expression in fetal and neonatal mice Am J Physiol Heart Circ Physiol, July 1, 2002; 283(1): H273 - H283. [Abstract] [Full Text] [PDF] |
||||